(Boursier.com) — NFL Biosciences, a biopharmaceutical company developing botanical drugs for the treatment of dependencies and addictions, has filed a new patent application aimed at protecting the administration of NFL-101 in combination with other smoking cessation treatments and in particular nicotine substitutes. The application was originally filed in the United States and will be extended internationally in accordance with NFL Biosciences’ intellectual property protection strategy. NFL intends to demonstrate the interest of combining NFL-101 with other smoking cessation treatments and in particular with nicotine substitute treatments: before the launch of dedicated clinical studies, NFL Biosciences filed a patent application to protect the administration of NFL -101 before attempting to quit concomitantly with the initiation of another smoking cessation treatment, particularly nicotine replacement therapy.
Nicotine substitutes include transdermal patches (patches), tablets, chewing gum, inhalers and nicotine spray. They are used as a substitute for cigarettes after stopping or reducing cigarette smoking to alleviate withdrawal symptoms due to stopping or reducing nicotine intake. The global market for smoking cessation drugs is estimated at nearly $6 billion (source: Coherent Market Insights); with an estimated growth of 6% over the next few years, it is nevertheless limited by a lack of more effective treatments without side effects. Despite a modest efficacy at 6 months, around 15.7% (source: EAGLES), nicotine substitutes represent 80% of the market. They are the benchmark treatments, because they have no significant side effects and because other drugs such as Champix/Chantix and Zyban, which have slightly higher efficacy (still at 6 months and according to EAGLES: 21.8% for Champix/ Chantix and 16.2% for Zyban) are sometimes poorly tolerated.
©2022 Boursier.com